Qiagen N.V. Stock News

In terms of QIAstat-Dx, QIAGEN (QGEN) continues to witness increased demand for system placements and growing consumables usage around the world.

QIAGEN (QGEN) QIAxcel Connect automates the analysis of the size and quality of isolated DNA and RNA.

This year the National Institutes of Health is set to request its biggest budget yet for 2024, on the heels of its previous biggest budget in 2023. As the COVID-19 pandemic fades from view, labs will

QIAGEN (QGEN) will develop a real-time in vitro PCR test that can be utilized to spot IDH1 gene mutations in AML patients in whole blood and bone marrow aspirates.

Beyond COVID-Sales, Qiagen demonstrated strong growth in its core businesses. Growth has historically increased faster than revenue, demonstrating the company's ability to achieve economies of scale.

Qiagen is seeing a pandemic-driven hangover in its financial results, but underlying double-digit revenue growth was ahead of expectations. The pandemic meaningfully accelerated system placements for

Qiagen N.V. (NYSE:QGEN ) Q4 2022 Earnings Conference Call February 8, 2023 9:00 AM ET Company Participants John Gilardi - Vice President, Head of Corporate Communications & Investor Relations Thierry

The ongoing double-digit sales growth in the non-COVID product portfolio contributed to QIAGEN's (QGEN) Q4 revenues.

Qiagen (QGEN) delivered earnings and revenue surprises of 12.77% and 3.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Qiagen (QGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

VENLO, Netherlands--( BUSINESS WIRE )--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the fourth quarter and full-year 2022.

The QuantiFERON franchise is a key driver behind QIAGEN's (QGEN) molecular diagnostics growth.

Investors are optimistic about QIAGEN (QGEN), led by progress in the test menu expansion strategy.

QIAGEN's (QGEN) acquisition of Verogen fortifies the company's position in the fast-growing field of Human ID and forensics.

QIAGEN's (QGEN) therascreen-based companion diagnostic detects KRAS G12C, a genetic mutation that is one of the most common KRAS variations related to cancer.